Pfizer Inc (PFE)

PFE on New York Consolidated

30.71USD
24 Apr 2014
Price Change (% chg)

$-0.21 (-0.68%)
Prev Close
$30.92
Open
$30.90
Day's High
$30.90
Day's Low
$30.20
Volume
24,963,923
Avg. Vol
28,838,341
52-wk High
$32.96
52-wk Low
$27.12

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.74
Market Cap (Mil.): $197,687.91
Shares Outstanding (Mil.): 6,393.53
Dividend: 0.26
Yield (%): 3.36

Financials

  PFE Industry Sector
P/E (TTM): 18.73 33.36 33.52
EPS (TTM): 1.65 -- --
ROI: 7.49 19.69 18.94
ROE: 14.45 20.38 19.71
Search Stocks

UPDATE 3-AstraZeneca plans spin-offs as cancer progress fuels bid talk

* Anti-PD-L1 product and three other drugs into Phase III

8:16am EDT

AstraZeneca flags cancer advances, silent on Pfizer bid talk

LONDON - AstraZeneca highlighted progress with new cancer drugs that may revive its fortunes as it posted a 17 percent fall in core earnings per share on Thursday, reflecting patent losses on profitable older medicines.

2:53am EDT

AstraZeneca flags cancer advances, silent on Pfizer bid talk

LONDON, April 24 - AstraZeneca highlighted progress with a new generation of cancer drugs that may revive its fortunes as it posted a 17 percent fall in core earnings per share on Thursday, reflecting patent losses on profitable older medicines.

2:25am EDT

Novartis and GSK trade assets as pharma industry reshapes

ZURICH/LONDON - Novartis and GlaxoSmithKline agreed to trade more than $20 billion worth of assets on Tuesday to bolster their best businesses and exit weaker ones as the drug industry contends with healthcare spending cuts and generic competition. | Video

22 Apr 2014

Valeant CEO breaks the mold in building drug empire

- At any given time, the acquisitive chief executive of Valeant Pharmaceuticals Inc is brokering multiple deal discussions and eyeing as many as 50 buying opportunities.

22 Apr 2014

NEWSMAKER-Valeant CEO breaks the mold in building drug empire

April 22 - At any given time, the acquisitive chief executive of Valeant Pharmaceuticals Inc is brokering multiple deal discussions and eyeing as many as 50 buying opportunities.

22 Apr 2014

UPDATE 4-Novartis and GSK trade assets as pharma industry reshapes

* Deals, plus talk of Pfizer-Astra deal, lift sector shares (Adds details on Lilly animal health unit, updates share movement)

22 Apr 2014

Deals and deal talk among pharmaceuticals lift Britain's FTSE

* FTSE 100 gains 0.9 pct * AstraZeneca surges on report of Pfizer approach * GlaxoSmithKline jumps on asset swap with Novartis (Updates with closing prices, adds technical detail) By Alistair Smout LONDON, April 22 - Corporate activity in the pharmaceutical sector on Tuesday pushed Britain's benchmark stock index to a two-week high and to within sight of a peak for this year. Drugmaker AstraZeneca rose 4.7 percent, with trading volumes in the stock more than three

22 Apr 2014

M&A activity in pharmaceuticals pushes UK's FTSE higher

* FTSE 100 up 1.1 pct * AstraZeneca surges on reported Pfizer bid interest * GlaxoSmithKline jumps on asset swap with Novartis (Adds detail, quote, updates prices) By Alistair Smout LONDON, April 22 - Merger and acquisition activity among drug companies drove Britain's top share index to a two-week high on Tuesday, putting it within sight of its peak for 2014. Drugmaker AstraZeneca surged 6.7 percent, with trading volumes in the stock over twice its 90-day average

22 Apr 2014

M&A activity in pharmaceuticals pushes UK's FTSE higher

* FTSE 100 up 1 pct * AstraZeneca surges on reported Pfizer bid interest * GlaxoSmithKline jumps on asset swap with Novartis (Adds detail, quote, updates prices) By Alistair Smout LONDON, April 22 - Merger and acquisition activity in the pharmaceutical sector drove Britain's top share index to a two-week high on Tuesday, putting it within sight of its peak for 2014. Drugmaker AstraZeneca surged 7.1 percent, with trading volumes in the stock nearly twice their 90-d

22 Apr 2014

Competitors

  Price Change
The Procter & Gamble Company (PG.N) $81.15 +0.79
Johnson & Johnson (JNJ.N) $99.96 -0.26
Novartis AG (NOVN.VX) CHF74.80 -1.45
Merck & Co., Inc. (MRK.N) $57.53 +0.03
Roche Holding Ltd. (ROG.VX) CHF255.20 -1.00
Abbott Laboratories (ABT.N) $38.43 -0.17
Bayer AG (BAYGn.DE) €97.01 +0.18
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.60 -0.45
AstraZeneca plc (AZN.L) 4,175.00p +132.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks